Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc has demonstrated impressive financial growth, with net product revenues increasing 140% to $607.6k in FY24 and a remarkable 223% increase in Q3 FY25 revenue year-over-year, reflecting strong demand for its product ARAKODA. The continued growth in ARAKODA deliveries, rising by 14% to 1,505 boxes in Q3 FY25, highlights the increasing market acceptance and potential for sustained revenue expansion. Furthermore, the favorable safety profile of tafenoquine presents opportunities for broader therapeutic applications, enhancing the company's commercialization prospects in the competitive pharmaceutical landscape.

Bears say

60 Degrees Pharmaceuticals Inc faces significant challenges reflected in its current financial performance, as evidenced by a reported gross loss of approximately $9,000 in Q3 FY24, which marks a concerning decline from a gross profit of $36,000 in the previous quarter, primarily due to a one-time inventory write-off. The firm's forward multiples are depressed amidst market volatility, compounded by low visibility on regulatory approvals and risks of dilution from future financing, creating an uncertain outlook for cash flow and profitability. Additionally, the company is exposed to commercial risks due to diminishing demand and potential market share loss, as evidenced by the emerging resistance to artemisinin treatments, which could further threaten the viability of its product pipeline.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.